from its Phase 1b/2 clinical
trial of ciforadenant, its adenosine A2A receptor antagonist, in patients with advanced refractory renal cell carcinoma (RCC).
The updated results support and refine the utility of the Adenosine Gene Signature (AdenoSig), which was discovered by Corvus,
as a predictive biomarker to identify RCC patients most likely to respond to treatment with ciforadenant. The discovery of the
AdenoSig was described in a research article published in Cancer Discovery in January 2020. In the publication, for 30 patients
with available tumor biopsies, AdenoSig positive patients had a 17% objective response rate (ORR) by RECIST criteria compared to
0% in AdenoSig negative patients. In the new data, which covers over 50 patients, the ORR remained 17% for the A denosine Gene Signature
and improved to 27% with the refined version of the test, which is based the measurement of CD68 positive myeloid cells, the downstream
target of adenosine.
The updated data covers 51 RCC patients that were treated with ciforadenant
monotherapy or in combination with Genentechs Tecentriq
(atezolizumab), an anti-PD-L1 antibody, and
whose tumors were biopsied to test with the AdenoSig. The data were made available in an on-demand, electronic poster format for
registered participants of the ASCO20 Virtual Scientific Program on May 29, 2020. The key updates from the presentation included:
31 patients (30 evaluable) were positive for the AdenoSig and 20 patients were negative. Patients had a median of three prior
therapies, including 86% that failed a prior anti PD-(L)1 therapy.
In the AdenoSig positive group, there were five partial responses (PR, RECIST) for an ORR of 17% and six additional patients
that had tumor regression not meeting the criteria for a PR.
In the AdenoSig negative group, there were no PRs and no patients with tumor regression.
In the AdenoSig positive group, the progression free survival (PFS) curve plateaued at 23% at 40 weeks, compared to declining
to 0% in the AdenoSig negative group.
In addition, the enrollment of new patients in the study was intended
to support the study and refinement of the AdenoSig.As part of this work, Corvus investigators demonstrated that CD68 positive
(CD68+) myeloid cells, which are known to be myeloid derived suppressor cells, are the downstream target of adenosine present in
the tumor microenvironment.Immunohistochemistry (IHC) testing showed that an increase of CD68+ myeloid cells in a tumor further
enriched the AdenoSig identification of responders to treatment with ciforadenant. This work indicates that the single CD68+ IHC
test could potentially be utilized to enrich patient selection for responding patients and as a substitute for the AdenoSig biomarker
previously utilized by Corvus. The key data related to CD68 presented in the poster include:
CD68 analysis was available for 53 patients, including 15 CD68 positive (CD68+) and 38 CD68 negative (CD68-) patients.
All but one patient in the study with a PR were in the CD68+ group.
The ORR in the CD68+ group was 26.7% (4 of 15), compared to an ORR of 2.6% (1 of 38) in the CD68- group.
Treatment with ciforadenant was associated with a reduction of infiltrating CD68+ cells in pre-treatment compared to on-treatment
tumor biopsies (paired to individual patients), supporting the biologic effects of ciforadenant and the potential predictive utility
of CD68 to identify RCC patients most likely to respond to treatment with ciforadenant.
To the extent that statements contained herein
are not descriptions of historical facts regarding Corvus, they are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995,
including statements related to the potential safety and efficacy of ciforadenant (CPI-444), the Companys ability to identify
and utilize the adenosine gene signature or the CD68+ gene for purposes of its clinical trials, including the Companys Phase
1b/2 clinical trial of ciforadenant. Such forward-looking statements involve substantial risks and uncertainties that could cause
the Companys clinical development programs, future results, performance, or achievements to differ significantly from those
expressed or implied by the forward-looking statements. For a description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company
in general, see Corvus reports filed with the Securities and Exchange Commission (SEC), including its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on April 30, 2020, as well as other documents that
may be filed by the Company from time to time with the SEC.
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CORVUS PHARMACEUTICALS, INC.
Date: May 29, 2020
/s/ Leiv Lea
Chief Financial Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020